(Reuters) – Drug developer Novavax Inc said on Monday it has completed patient enrollment in the late-stage study of its COVID-19 vaccine in the United States and Mexico.
(Reporting by Manas Mishra in Bengaluru; Editing by Shounak Dasgupta)
Novavax completes enrollment in U.S. late-stage trial of COVID vaccine
